Genset Corporation

Last updated
Genset
Industry biotechnology
Founded1989
Successor Serono
Headquarters Paris, France

Genset, a biotechnology company, was established in 1989 in Paris, France with Pascal Brandys as its first president. [1]

History

Genset was listed on the NASDAQ and the Paris Bourse (now NYSE Euronext) in 1996. [2] Genset rapidly became the European flagship company [2] in the field of genomics and became the second-largest biotechnology company in Europe in 1999. At that time, the company reported identifiable assets of EUR 80.9 million and had subsidiaries in the United States, Japan, Singapore, and Australia. Genset was a pioneer in private human genome research. [3] In 1994, Genset started the first large scale program to analyze the regulatory sequences of the human genome and in 1997 also initiated the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases. [4] [5] The company also created the business model of pharmacogenomics and started the first pharmacogenomics research program in the world in collaboration with Abbott Laboratories in 1997. [6]

After 2000 Genset changed its strategy to focus on drug development, leading to the departure of its president and other founders.[ citation needed ] The strategy shift proved unsuccessful and Genset was acquired by Serono of Switzerland in 2002, now part of Merck Serono.[ citation needed ] In 2006, Merck launched a takeover bid for Serono. [7]

Related Research Articles

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

<span class="mw-page-title-main">Ernesto Bertarelli</span> Swiss-Italian billionaire

Ernesto Silvio Maurizio Bertarelli is an Italian-born Swiss billionaire businessman and philanthropist.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development is a contract research organization (CRO) headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide. Labcorp Drug Development claims to provide the world's largest central laboratory network.

<span class="mw-page-title-main">Pharmacogenomics</span> Study of the role of the genome in drug response

Pharmacogenomics is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of a patient affects their response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response, by correlating DNA mutations with pharmacokinetic, pharmacodynamic, and/or immunogenic endpoints.

<span class="mw-page-title-main">Human Genome Sciences</span> Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

deCODE genetics is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 by Kári Stefánsson with the aim of using population genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries "to develop novel methods to identify, treat and prevent diseases."

Serono was a biotechnology company headquartered in Geneva, Switzerland. It was acquired by the German pharmaceutical company Merck in 2006. The company was founded as the Serono Pharmacological Institute by Cesare Serono in 1906 in Rome, Italy. A key step in its development was the discovery of a method of extracting urinary gonadotropins by Dr. Piero Donini. Serono was incorporated in 1987 and the holding company, Ares-Serono S.A., changed its name to Serono S.A. in May 2000.

<span class="mw-page-title-main">Thiopurine methyltransferase</span>

Thiopurine methyltransferase or thiopurine S-methyltransferase (TPMT) is an enzyme that in humans is encoded by the TPMT gene. A pseudogene for this locus is located on chromosome 18q.

This page provides an alphabetical list of articles and other pages about biotechnology.

Pascal Brandys is a French engineer and entrepreneur. He is a graduate of the École Polytechnique and received his M.S. in Economic Systems from Stanford University in 1982. He began his career in venture capital first in Tokyo and then in London, where he contributed to the first wave of biotechnology companies in Europe. He was the former president and founder of Genset Corporation, which became the European flagship in the field of genomics and at some point the second largest biotechnology company in Europe. He was also a co-founder and former president of France Biotech, the trade association of biotechnology companies in France. In 2001 he co-founded the biotechnology holding company Biobank in San Diego. In 2020 he co-founded Phylex BioSciences, Inc., a company based in San Diego developing a universal vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In 2022 he published positive results of a protection study with the vaccine.

Charles Thomas Caskey, also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Human Genetics at Baylor College of Medicine, and served as editor of the Annual Review of Medicine from 2001 to 2019. He was a member of the editorial boards of the Proceedings of the National Academy of Sciences, Science, the Encyclopedia of Molecular Medicine and numerous other medical and scientific journals.

Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.

Samir Kumar Brahmachari is an Indian biophysicist and Former Director General of the Council of Scientific & Industrial Research (CSIR) and Former Secretary, Department of Scientific and Industrial Research (DSIR), Government of India. He is the Founder Director of Institute of Genomics and Integrative Biology (IGIB), New Delhi and the Chief Mentor of Open Source for Drug Discovery (OSDD) Project. He is the recipient of J.C Bose Fellowship Award, DST (2012). In addition, he is one of the featured researchers in the India Cancer Research Database developed by Institute of Bioinformatics (IOB), Bangalore with support from the Department of Biotechnology, Government of India.

Manteia Predictive Medicine S.A. was a start-up company created in November 2000 as a spin-off of Serono, a Swiss-based biotechnology company, now part of Merck-Serono, by private founders. Its aim was to provide preventive and curative treatment guidelines for common and complex diseases. These guidelines were envisaged as composed of two parts:

<span class="mw-page-title-main">Michael R. Hayden</span>

Michael R. Hayden, is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only four such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD).

<span class="mw-page-title-main">William A. Haseltine</span> American biologist (born 1944)

William A. Haseltine is an American scientist, businessman, author, and philanthropist. He is known for his groundbreaking work on HIV/AIDS and the human genome.

<span class="mw-page-title-main">Eric Schadt</span> American scientist

Eric Emil Schadt is an American mathematician and computational biologist. He is founder and former chief executive officer of Sema4, a patient-centered health intelligence company, and dean for precision medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously founding director of the Icahn Institute for Genomics and Multiscale Biology and chair of the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">Gerardo Jiménez Sánchez</span>

Gerardo Jiménez Sánchez is a Mexican-born pediatrician, scientist and businessman. Along with David Valle and Barton Childs, he completed the first medical analysis of the human genome. He was founder and director of the first National Institute of Genomic Medicine in Latin America (INMEGEN) and leader of the team that developed the Genomic Map of the mexican population.

<span class="mw-page-title-main">Mark Boguski</span> American pathologist (died 2021)

Mark S. Boguski was an American pathologist specializing in computational analysis and structural biology, He was elected in 2001 to the U.S. National Academy of Medicine, and was a Fellow of the American College of Medical Informatics.

The Exploratory Science Center (ESC) is a pharmaceutical company based in Cambridge, MA. The disease agnostic research site was founded in 2016, and was led by Daria Hazuda until 2021. In late 2021 Juan Alvarez took on leadership as the interim head and Marc Levesque took on leadership in 2022. The Exploratory Science Center is a subsidiary of Merck & Co.

References

  1. Genset: 1989 Harvard Business School Case Study Paul A. Gompers, Amy L. Burroughs
  2. 1 2 Genset Initial Public Offering Harvard Business School Case Study Paul A. Gompers, Jeffrey Anapolsky
  3. Capitalizing on the genome Nature Genetics 13, 1-1 (1996) Editorial
  4. Drug firms discuss linking up to pursue disease-causing genes The Wall Street Journal (4 March 1999) Robert Langreth, Michael Waldhoz and Stephen D. Moore
  5. Decoding the literature on genetic variation Nature Biotechnology 21, 21-29 (2003) Roger Coronini
  6. Pharmacogenomics Nature Biotechnology 18, 40-42 (2000) Technologies
  7. "Merck s'empare du suisse Serono pour 10,6 milliards d'euros". Les Echos (in French). 2006-09-22. Retrieved 2022-08-20.